allogeneic-cell-therapy
(2)
Be Biopharma
Be Biopharma (Be Bio) is a Cambridge, Massachusetts biotechnology company pioneering a new class of therapies called Engineered B Cell Medicines (BCMs). By precisely gene-editing a patient's own B cells - nature's protein factories that can secrete high volumes of protein for decades - Be Bio aims to deliver durable, potentially re-dosable treatments for hemophilia, rare genetic diseases, and other serious conditions. Founded in 2020 out of Seattle Children's Research Institute and Longwood Fund, the company has raised roughly $356 million and, as of early 2025, advanced to a multi-program clinical-stage company led by CEO Joanne Smith-Farrell, Ph.D.
Andrew Schiermeier
Andrew Schiermeier is the President and CEO of AvenCell Therapeutics, a clinical-stage biotech in Cambridge, Massachusetts and Dresden, Germany building switchable, universal CAR-T cell therapies for hard-to-treat cancers like acute myeloid leukemia. An engineer-turned-operator with a Harvard PhD in applied mathematics, he spent two decades across startups and global pharma - five years at CRISPR pioneer Intellia Therapeutics rising to COO, and a stint running Merck KGaA's oncology business across 60-plus countries - before taking AvenCell's helm in 2021 and leading its $112 million Series B in 2024.